n(omega)-hydroxyarginine has been researched along with eflornithine in 2 studies
| Studies (n(omega)-hydroxyarginine) | Trials (n(omega)-hydroxyarginine) | Recent Studies (post-2010) (n(omega)-hydroxyarginine) | Studies (eflornithine) | Trials (eflornithine) | Recent Studies (post-2010) (eflornithine) |
|---|---|---|---|---|---|
| 139 | 0 | 24 | 2,377 | 93 | 268 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, KL; Chin-Dusting, JF; Harris, EE; Huynh, NN | 1 |
| Aloj, SM; Chiaviello, A; Paciello, I; Palumbo, G; Veneziani, BM | 1 |
2 other study(ies) available for n(omega)-hydroxyarginine and eflornithine
| Article | Year |
|---|---|
The vascular effects of different arginase inhibitors in rat isolated aorta and mesenteric arteries.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Arginase; Arginine; Boronic Acids; Eflornithine; Endothelium, Vascular; In Vitro Techniques; Male; Mesenteric Arteries; Nitric Oxide; Nitric Oxide Synthase; Rats; Rats, Sprague-Dawley; Tachyphylaxis; Valine; Vasodilator Agents | 2009 |
Cells derived from normal or cancer breast tissue exhibit different growth properties when deprived of arginine.
Topics: Arginine; Breast; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Eflornithine; Female; Humans | 2012 |